Fig. 4: Ulotaront enhances excitatory synaptic transmission in hippocampal CA1.

Schematics of animal model (A, top), brain area (A, bottom), recording strategy (B, top) and experimental time course (B, bottom). Field EPSP were measured in the stratum radiatum of the CA1 by means of extracellular field potential recordings upon stimulation of the Schaffer Collateral pathway (SC). Peak amplitude and initial slope of fEPSP were analyzed during pre-drug baseline condition and for the last 5 min of treatment with ulotaront (10 μM and 30 μM) or vehicle. C Representative average traces of fEPSP responses before (left) and during compound application (right). D, E Peak amplitude of fEPSP in CA1. D fEPSP amplitude during baseline condition (b) and upon bath application (t) of ulotaront (10 μM and 30 μM) or vehicle. E Effect of treatment with vehicle control vs ulotaront on fEPSP amplitude. Data were normalized to baseline and presented as average time course (left) as well as summary plot (right; each dot represents a brain slice, as in (D)). F, G Analysis on fEPSP slope, corresponding to (D, E). Data are mean ± s.e.m; n = 10 -14 slices. For statistics, see Table S1. ns, not significant; *p < 0.05.